Peptide Based Antibacterial Coating

Information

  • Research Project
  • 7497561
  • ApplicationId
    7497561
  • Core Project Number
    R44DK072560
  • Full Project Number
    5R44DK072560-03
  • Serial Number
    72560
  • FOA Number
    PA-06-20
  • Sub Project Id
  • Project Start Date
    9/20/2005 - 18 years ago
  • Project End Date
    7/31/2010 - 13 years ago
  • Program Officer Name
    MOXEY-MIMS, MARVA M.
  • Budget Start Date
    8/1/2008 - 15 years ago
  • Budget End Date
    7/31/2010 - 13 years ago
  • Fiscal Year
    2008
  • Support Year
    3
  • Suffix
  • Award Notice Date
    8/28/2008 - 15 years ago
Organizations

Peptide Based Antibacterial Coating

[unreadable] DESCRIPTION (provided by applicant): The objective of this work is to develop dual function antibacterial coatings that prevent biofilm formation and thrombus. A key feature of this technology is that it will prevent biofilm formation without an associated risk of creating antibiotic resistant bacteria. The coating combines a novel protein resistant polymer with an antibacterial peptide. The peptide kills bacteria through a multi- tiered mechanism that is fundamentally different from that of clinical antibiotics and is therefore unlikely to promote resistance. Coatings will be produced by binding the peptide to surfaces in two modes: via a flexible tether and entrapment. A layer of the antibacterial peptide prepared in this way should be safe, functional, and long-lasting. This Phase II SBIR plan focuses on meeting requirements for short term central venous catheters. First, coating constituents will be selected to maximize activity. Activity and mode of action will be characterized with a close look at covalently tethered versus physically bound peptides. As a part of this process, structural and functional relationships of surface bound antimicrobials will be examined. Second, methods will be developed to ensure robust performance of coatings under physiological conditions. Efficacy over time under these conditions will be measured, where efficacy criteria include biofilm inhibition as well as nonthrombogenicity. Prototype catheters coated with this technology will then be produced and tested against clinically relevant bacteria including methicillin-resistant strains of Staphylococcus aureus and Staphylococcus epidermidis. The plan will be completed with an in vivo evaluation of prototypes using a model of central venous catheter infection in rats. Commercial applications include catheters, medical, optical and dental devices. [unreadable] [unreadable] [unreadable]

IC Name
NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES
  • Activity
    R44
  • Administering IC
    DK
  • Application Type
    5
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    423190
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    847
  • Ed Inst. Type
  • Funding ICs
    NIDDK:423190\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    ALLVIVO VASCULAR, INC.
  • Organization Department
  • Organization DUNS
    179043893
  • Organization City
    LAKE FOREST
  • Organization State
    CA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    92630
  • Organization District
    UNITED STATES